Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01668550
Other study ID # CRUKD/07/061
Secondary ID
Status Terminated
Phase Phase 1
First received May 31, 2012
Last updated February 1, 2018
Start date October 2012
Est. completion date May 2016

Study information

Verified date July 2016
Source Cancer Research UK
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the maximum tolerated dose of the oral Src/Abl inhibitor AZD0424, and to find tolerable and effective AZD0424 combination regimens for the treatment of advanced solid tumours


Description:

AZD0424 is a potent orally available, potent (IC50 approximately 4 nM) inhibitor of Src and ABL1 kinases with additional activity against Src family kinase (SFK) members including Yes and Lck. AZD0424 was selective for SFKs and ABL1 kinase over C-terminal Src kinase (a negative regulator of Src) and a range of other kinase targets. The anti-cancer activity of AZD0424 is thought to be mediated primarily by anti-migratory and anti-invasive signalling and, as such, it is expected that in the late stage cancer setting strong signals of efficacy with this compound used as a single agent are unlikely, requiring it to be administered in combination with other anti-cancer agents.

In summary the study will be performed in four main stages:

- AZD0424 monotherapy, dose escalation: Phase Ia single agent (AZD0424) dose escalation study to determine the MTD.

- AZD0424 monotherapy, dose expansion: Phase Ib single agent dose expansion at MTD (up to six additional patients may be recruited in order to provide paired tumour biopsies for PD analysis).

- Combination arm dose escalation: Provided that it is deemed appropriate (after review of available clinical data from the monotherapy part of the trial, and available preclinical and published data on the combination), a Phase Ia dose escalation arm of AZD0424 in combination with the selected agent will proceed to determine the MTD for the combination and a recommended Phase II dose.

- Combination arm dose expansion: Phase Ib combination arm using the recommended Phase II dose for both AZD0424 and the combination agent.


Recruitment information / eligibility

Status Terminated
Enrollment 43
Est. completion date May 2016
Est. primary completion date May 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically or cytologically proven solid tumour, refractory to conventional treatment, or for which no conventional therapy exists or is declined by the patient or for whom there is the prospect of clinical benefit

- Life expectancy of at least 12 weeks

- World Health Organisation (WHO) performance status of 0-2

- Haematological and biochemical indices within the ranges shown below. These measurements must be performed within one week (Day -7 to Day 1) before the patient receives AZD0424

- Haemoglobin (Hb) = 9.0 g/dL

- Absolute neutrophil count (ANC) = 1.5 x 109/L

- Platelet count = 100 x 109/L

- Serum bilirubin = 1.5 x upper limit of normal (ULN)

- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 2.5 x (ULN) Either: Calculated creatinine clearance = 50 mL/min Or Or Isotope Clearance measurement = 50 mL/min (uncorrected)

- 18 years or over

- Written (signed and dated) informed consent and be capable of co-operating with treatment and follow-up

- MTD Expansion cohorts only: A tumour which is safely accessible for biopsy (single and combination)

Exclusion Criteria:

- Radiotherapy (except for palliative reasons), endocrine therapy, immunotherapy or chemotherapy during the previous four weeks (six weeks for nitrosoureas, Mitomycin-C and four weeks for investigational medicinal products) before treatment.

- Ongoing toxic manifestations of previous treatments. Exceptions to this are alopecia or certain Grade 1 toxicities, which in the opinion of the Investigator and the DDO should not exclude the patient.

- Symptomatic brain metastases (if brain metastases are present they must have been stable for > 3 months).

- Patients with evidence of interstitial lung disease (bilateral, diffuse, parenchymal lung disease).

- Patients with a peanut allergy will be excluded.

- Ability to become pregnant (or already pregnant or lactating). However, those female patients who have a negative serum or urine pregnancy test before enrollment and agree to use two highly effective forms of contraception as detailed in the protocol are considered eligible.

- Male patients with partners of child-bearing potential (unless they agree to take measures not to father children by using one form of highly effective contraception as detailed in the protocol). Men with pregnant or lactating partners should be advised to use barrier method contraception (for example, condom plus spermicidal gel) to prevent exposure to the foetus or neonate.

- Major thoracic or abdominal surgery from which the patient has not yet recovered.

- At high medical risk because of non-malignant systemic disease including active uncontrolled infection.

- Known to be serologically positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV).

- Resting ECG with measurable QTc interval of >480 msec (mean value and manually verified) of at least 3 time points within a 24 hour period.

- Concurrent hypotension defined as a baseline supine blood pressure (BP) systolic < 90 mmHg.

- Concurrent congestive heart failure, prior history of class III/ IV cardiac disease (New York Heart Association [NYHA]), prior history of cardiac ischaemia or prior history of cardiac arrhythmia within 6 months. Coronary angioplasty or stenting in the previous 12 months.

- Is a participant or plans to participate in another interventional clinical trial, whilst taking part in this Phase Ia/Ib study of AZD0424 single agent and in combination. Participation in an observational, counseling or psychological trial would be acceptable.

- Any other condition which in the Investigator's opinion would not make the patient a good candidate for the clinical trial.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
AZD0424
AZD0424 will be administered as a flat dose orally once a day. One treatment cycle consists of 28 days of continuous drug administration with AZD0424, with the flexibility to introduce treatment breaks if required due to cumulative toxicity. Combination agents and treatment regimen with AZD0424 will be confirmed and approved at a later date.

Locations

Country Name City State
United Kingdom Belfast City Hospital Belfast
United Kingdom Edinburgh Cancer Centre - Western General Hospital Edinburgh
United Kingdom Oxford University Hospitals NHS Trust Oxford

Sponsors (1)

Lead Sponsor Collaborator
Cancer Research UK

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Establishing the Maximum Tolerated Dose (MTD) of AZD0424 alone and in combination
Primary Determining the causality and duration of adverse events observed during the study according to NCI CTCAE Version 4.02
Secondary Determining the correlation between PK studies and toxicity and/or efficacy.
Secondary Measurement of urinary and serum N terminal Telopeptide (NTx) and serum C-terminal peptide (CTx) levels before the first AZD0424 administration and then following first AZD0424 administration, to evaluate bone turnover
Secondary Measurement of the following biomarkers in tumour tissue before and after the first AZD0424 administration: p-Src, MKI67 (Ki-67), p-PAX, p-CRKL, p-FAK.
Secondary Evaluate responses (stable disease (SD), partial response (PR) or complete response (CR)) in any of the patients as determined by Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05514132 - A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours Phase 1
Terminated NCT04949425 - A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours Phase 1
Not yet recruiting NCT05537051 - A Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-β) in Patients With Advanced Solid Tumours Phase 1
Completed NCT02579226 - A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors. Phase 1
Completed NCT01058538 - A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours Phase 1/Phase 2
Completed NCT02588105 - Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer Phase 1
Recruiting NCT03852823 - Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours Phase 1
Not yet recruiting NCT06380816 - A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer Phase 1/Phase 2
Completed NCT01585701 - Phase I Study of AT13148, a Novel AGC Kinase Inhibitor Phase 1
Completed NCT03101839 - Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours Phase 1
Completed NCT03150368 - Extended Use of ModraDoc006/r Phase 1
Active, not recruiting NCT02389842 - PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib Phase 1
Terminated NCT01581060 - Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours Phase 1/Phase 2
Terminated NCT04959266 - A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib Phase 1
Completed NCT04462952 - Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours Phase 1
Active, not recruiting NCT03518606 - Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours Phase 1/Phase 2
Completed NCT02430311 - The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour. Phase 1
Terminated NCT01859351 - Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours Phase 1
Completed NCT01163903 - Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours Phase 1
Recruiting NCT05804526 - A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours Phase 1/Phase 2